Clonal Hematopoiesis and Risk of Incident Lung Cancer
Authors:
- Ruiyi TianRTRuiyi Tian
- Jie LiuJLJie Liu
- Xiaoyu ZongXZXiaoyu Zong
- Buu TruongBTBuu Truong
- Stephanie ZhaoSZStephanie Zhao
- Mesbah UddinMUMesbah Uddin
- Abhishek NiroulaANAbhishek Niroula
- Christopher A. MillerCMChristopher A. Miller
- Semanti MukherjeeSMSemanti Mukherjee
- Brendan T. HeidenBHBrendan T. Heiden
- Jingqin LuoJLJingqin Luo
- 1 March 2023
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (7) , 1423-1433
Abstract
PURPOSE: To prospectively examine the association between clonal hematopoiesis (CH) and subsequent risk of lung cancer. METHODS: Among 200,629 UK Biobank (UKBB) participants with whole-exome sequencing, CH was identified in a nested case-control study of 832 incident lung cancer cases and 3,951 controls (2006-2019) matched on age and year at blood draw, sex, race, and smoking status. A similar nested case-control study (141 cases/652 controls) was conducted among 27,975 participants with whole-exome sequencing in the Mass General Brigham Biobank (MGBB, 2010-2021). In parallel, we compared CH frequency in published data from 5,003 patients with solid tumor (2,279 lung cancer) who had pretreatment blood sequencing performed through Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets. RESULTS: In UKBB, the presence of CH was associated with increased risk of lung cancer (cases: 12.5% v controls: 8.7%; multivariable-adjusted odds ratio [OR], 1.36; 95% CI, 1.06 to 1.74). The association remained robust after excluding participants with chronic obstructive pulmonary disease. No significant interactions with known risk factors, including polygenic risk score and C-reactive protein, were identified. In MGBB, we observed similar enrichment of CH in lung cancer (cases: 15.6% v controls: 12.7%). The meta-analyzed OR (95% CI) of UKBB and MGBB was 1.35 (1.08 to 1.68) for CH overall and 1.61 (1.19 to 2.18) for variant allele frequencies ≥ 10%. In Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets, CH with a variant allele frequency ≥ 10% was enriched in pretreatment lung cancer compared with other tumors after adjusting for age, sex, and smoking (OR for lung v breast cancer: 1.61; 95% CI, 1.03 to 2.53). CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.Keywords
This publication has 49 references indexed in Scilit:
- The Ensembl Variant Effect PredictorGenome Biology, 2016
- Comprehensive genomic profiles of small cell lung cancerNature, 2015
- UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old AgePLOS Medicine, 2015
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA SequenceNew England Journal of Medicine, 2014
- Age-Related Clonal Hematopoiesis Associated with Adverse OutcomesNew England Journal of Medicine, 2014
- Age-related mutations associated with clonal hematopoietic expansion and malignanciesNature Medicine, 2014
- Clinical and biological implications of driver mutations in myelodysplastic syndromesBlood, 2013
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Case-control studies: basic conceptsInternational Journal of Epidemiology, 2012
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011